Health Care [ 8/12 ] | Pharmaceuticals [ 29/73 ]
NASDAQ | Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States.
The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain.
It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate.
The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023.
Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 25 | -0.62 Increased by +82.54% | -0.42 Decreased by -47.62% |
| Mar 6, 25 | -0.56 Increased by +61.11% | -0.43 Decreased by -30.23% |
| Nov 6, 24 | -0.40 | -0.41 Increased by +2.44% |
| Aug 13, 24 | -0.39 | -0.35 Decreased by -11.43% |
| May 16, 24 | -3.55 | -0.46 Decreased by -671.74% |
| Feb 28, 24 | -1.44 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -15.99 M Decreased by -89.97% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 242.00 K Increased by +N/A% | -14.56 M Decreased by -87.48% | Decreased by -6.02 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -10.27 M Decreased by -64.25% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -9.01 M Decreased by -121.68% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -8.42 M Decreased by -74.48% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -7.77 M Decreased by -3.42% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 - | -6.25 M - | Decreased by N/A% - |
| Jun 30, 23 | 50.00 M - | 41.56 M - | Increased by +83.13% - |